Cargando…

Effect on HIV-1 viral replication capacity of DTG-resistance mutations in NRTI/NNRTI resistant viruses

BACKGROUND: Recommended regimens for HIV-positive individuals include the co-administration of dolutegravir (DTG) with two reverse transcriptase inhibitors (RTIs). Although rare, emerging resistance against DTG is often associated with the R263K substitution in integrase. In-vitro-selected R263K was...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pham, Hanh T., Mesplède, Thibault, Wainberg, Mark A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4851780/ https://www.ncbi.nlm.nih.gov/pubmed/27130466 http://dx.doi.org/10.1186/s12977-016-0265-x

Ejemplares similares

High Prevalence of NRTI and NNRTI Drug Resistance Among ART-Experienced, Hospitalized Inpatients
por: Bossard, Claire, et al.
Publicado: (2021)

Cost-effectiveness of 2NRTI+NNRTI versus 2NRTI+PI as the initial cART regimen
por: Aragão, F, et al.
Publicado: (2010)

The effects of ART on the dynamics of lipid profiles in Chinese Han HIV-infected patients: comparison between NRTI/NNRTI and NRTI/INSTI
por: Liu, Shengnan, et al.
Publicado: (2023)

633. Nanopore Sequencing and In-house Bioinformatic Pipeline for Rapid and Accurate Detection of NRTI, NNRTI, PI, and INSTI Drug Resistance Mutations
por: Salvaña, Edsel Maurice, et al.
Publicado: (2023)

The M50I polymorphic substitution in association with the R263K mutation in HIV-1 subtype B integrase increases drug resistance but does not restore viral replicative fitness
por: Wares, Melissa, et al.
Publicado: (2014)

Resistance against Integrase Strand Transfer Inhibitors and Relevance to HIV Persistence
por: Mesplède, Thibault, et al.
Publicado: (2015)

The R263K Dolutegravir Resistance-Associated Substitution Progressively Decreases HIV-1 Integration
por: Mesplède, Thibault, et al.
Publicado: (2017)

Long-term treatment outcomes of ritonavir-boosted lopinavir monotherapy among HIV-infected patients who experienced NRTI and NNRTI failure
por: Manosuthi, Weerawat, et al.
Publicado: (2012)

Treatment outcomes and plasma level of ritonavir-boosted lopinavir monotherapy among HIV-infected patients who had NRTI and NNRTI failure
por: Manosuthi, Weerawat, et al.
Publicado: (2009)

Erratum for Mesplède et al., “The R263K Dolutegravir Resistance-Associated Substitution Progressively Decreases HIV-1 Integration”
por: Mesplède, Thibault, et al.
Publicado: (2018)

Implications for the future of the HIV epidemic if drug resistance against dolutegravir cannot occur in first-line therapy
por: Wainberg, Mark A, et al.
Publicado: (2015)

What if HIV were unable to develop resistance against a new therapeutic agent?
por: Wainberg, Mark A, et al.
Publicado: (2013)

HIV drug resistance against strand transfer integrase inhibitors
por: Anstett, Kaitlin, et al.
Publicado: (2017)

The R263K mutation in HIV integrase that is selected by dolutegravir may actually prevent clinically relevant resistance to this compound
por: Wainberg, Mark, et al.
Publicado: (2014)

The latest evidence for possible HIV-1 curative strategies
por: Pham, Hanh Thi, et al.
Publicado: (2018)

Is Resistance to Dolutegravir Possible When This Drug Is Used in First-Line Therapy?
por: Mesplède, Thibault, et al.
Publicado: (2014)

HIV-1 group O integrase displays lower susceptibility to raltegravir and has a different mutational pathway for resistance than HIV-1 group M
por: Depatureaux, Agnès, et al.
Publicado: (2014)

Integrase Strand Transfer Inhibitors in HIV Therapy
por: Mesplède, Thibault, et al.
Publicado: (2013)

Pharmaceutical, clinical, and resistance information on doravirine, a novel non-nucleoside reverse transcriptase inhibitor for the treatment of HIV-1 infection
por: Pham, Hanh Thi, et al.
Publicado: (2020)

Low-Frequency NNRTI-Resistant HIV-1 Variants and Relationship to Mutational Load in Antiretroviral-Naïve Subjects
por: Gupta, Shaili, et al.
Publicado: (2014)

Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI
por: Torti, Carlo, et al.
Publicado: (2011)

Will LEDGIN molecules be able to play a role in a cure for HIV infection?
por: Mesplède, Thibault, et al.
Publicado: (2016)

HIV-1 Resistance to Islatravir/Tenofovir Combination Therapy in Wild-Type or NRTI-Resistant Strains of Diverse HIV-1 Subtypes
por: Cilento, Maria E., et al.
Publicado: (2023)

Fitness Impaired Drug Resistant HIV-1 Is Not Compromised in Cell-to-Cell Transmission or Establishment of and Reactivation from Latency
por: Bastarache, Sophie M., et al.
Publicado: (2014)

HTA and HIV: The Case of Dual NRTI Backbones in the Italian Setting
por: Garagiola, Elisabetta, et al.
Publicado: (2020)

Identification of the Critical Sites of NNRTI-Resistance in Reverse Transcriptase of HIV-1 CRF_BC Strains
por: Huang, Yang, et al.
Publicado: (2014)

High level of HIV drug resistance informs dolutegravir roll-out and optimized NRTI backbone strategy in Mozambique
por: Carnimeo, V, et al.
Publicado: (2021)

Nonhuman Primates and Humanized Mice for Studies of HIV-1 Integrase Inhibitors: A Review
por: Hassounah, Said A., et al.
Publicado: (2016)

Emergency of Primary NNRTI Resistance Mutations without Antiretroviral Selective Pressure in a HAART-Treated Child
por: Machado, Elizabeth S., et al.
Publicado: (2009)

Lersivirine: a new NNRTI active across HIV-1 subtypes with a unique resistance profile
por: Mori, J, et al.
Publicado: (2010)

Discovery, synthesis, and optimization of an N-alkoxy indolylacetamide against HIV-1 carrying NNRTI-resistant mutations from the Isatis indigotica root
por: Xu, Chengbo, et al.
Publicado: (2020)

2508. Virologic Suppression in Patients Switched to BIC/TAF/FTC with Baseline NRTI and/or INSTI Resistance
por: Natali, Kayla M, et al.
Publicado: (2019)

The state of PI monotherapy and NRTI-sparing therapy
por: Arribas, JR
Publicado: (2010)

Increasing trends in primary NNRTI resistance among newly HIV-1-diagnosed individuals in Buenos Aires, Argentina
por: Rodriguez-Rodrigues, Nahuel, et al.
Publicado: (2013)

Cenicriviroc blocks HIV entry but does not lead to redistribution of HIV into extracellular space like maraviroc
por: Kramer, Victor, et al.
Publicado: (2014)

Treatment Switch to Dolutegravir With 2 Nucleoside Reverse-Transcriptase Inhibitors (NRTI) in Comparison to Continuation With Protease Inhibitor/Ritonavir Among Patients With Human Immunodeficiency Virus at Risk for Prior NRTI Resistance: A Cohort Analysis of Real-World Data
por: Sangaré, Mohamed N’dongo, et al.
Publicado: (2020)

Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure
por: Mesplède, Thibault, et al.
Publicado: (2013)

HIV Drug Resistance Mutations in Non-B Subtypes After Prolonged Virological Failure on NNRTI-Based First-Line Regimens in Sub-Saharan Africa
por: Kityo, Cissy, et al.
Publicado: (2017)

High Prevalence of Doravirine Resistance in HIV-1-Infected Patients with Virological Failure to an NNRTI-Based Single-Tablet Regimen
por: Tsai, Hung-Chin, et al.
Publicado: (2022)

Conservation Patterns of HIV-1 RT Connection and RNase H Domains: Identification of New Mutations in NRTI-Treated Patients
por: Santos, André F. A., et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_uhtpcsudpfig6h25k5r3iquoav